Predict your next investment

Venture Capital
casdincapital.com

See what CB Insights has to offer

Investments

180

Portfolio Exits

47

Funds

2

About Casdin Capital

Casdin Capital is an investment firm focused on the life sciences and healthcare industry.

Casdin Capital Headquarter Location

1350 Avenue of the Americas Suite 1140

New York, New York, 10019,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Casdin Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Casdin Capital in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Research containing Casdin Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Casdin Capital in 4 CB Insights research briefs, most recently on Feb 16, 2021.

Latest Casdin Capital News

Invetx Raises $60.5M in Series B Funding

May 11, 2022

Invetx , a Boston, MA-based pioneer in protein-based therapeutics for animal health, raised $60.5m in Series B financing. The round was led by F-Prime Capital, Novo Holdings, GV (formerly Google Ventures) and Eight Roads, with participation from existing investors Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. The company intends to use the funds to advance its monoclonal antibody (mAb) pipeline and pursue market approvals for therapeutics targeting chronic and serious diseases in dogs and cats. Led by Juergen Horn, PhD, chief executive officer, Invetx has built an integrated, iscovery, development, and manufacturing platform to create fully species-specific, optimized and half-life extended product candidates. By leveraging validated biotechnologies from human health and optimizing them for application in veterinary medicine, the company can generate differentiated antibodies to treat a wide variety of chronic and serious diseases in animals. Invetx has a broad pipeline of biotherapeutics in various therapeutic areas and expects to advance multiple candidates in development with product approvals anticipated potentially as early as 2025. In addition, the company has established a discovery, development, and commercialization partnership with Boehringer Ingelheim to pursue novel programs in addition to its own product portfolio. Invetx has also expanded its collaborations with AbCellera, Twist Bioscience and Wuxi Biologics. FinSMEs 10/05/2022

Casdin Capital Investments

180 Investments

Casdin Capital has made 180 investments. Their latest investment was in Character Biosciences as part of their Series A on May 5, 2022.

CBI Logo

Casdin Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/17/2022

Series A

Character Biosciences

$18M

Yes

2

5/17/2022

Series B

Remix Therapeutics

$70M

Yes

5

5/10/2022

Series B

MOMA Therapeutics

$150M

No

7

4/11/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

3/24/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/17/2022

5/17/2022

5/10/2022

4/11/2022

3/24/2022

Round

Series A

Series B

Series B

Series B

Series B

Company

Character Biosciences

Remix Therapeutics

MOMA Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$18M

$70M

$150M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

5

7

10

10

Casdin Capital Portfolio Exits

47 Portfolio Exits

Casdin Capital has 47 portfolio exits. Their latest portfolio exit was Amunix on December 21, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/21/2021

Acquired

$99M

10

12/10/2021

IPO

$99M

1

11/1/2021

IPO

18

10/1/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

8/9/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/21/2021

12/10/2021

11/1/2021

10/1/2021

8/9/2021

Exit

Acquired

IPO

IPO

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

10

1

18

10

10

Casdin Capital Fund History

2 Fund Histories

Casdin Capital has 2 funds, including Casdin Private Growth Equity Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/9/2020

Casdin Private Growth Equity Fund

$179M

1

2/28/2018

Casdin Venture Opportunities Fund

$99M

10

Closing Date

11/9/2020

2/28/2018

Fund

Casdin Private Growth Equity Fund

Casdin Venture Opportunities Fund

Fund Type

Status

Amount

$179M

$99M

Sources

1

10

Casdin Capital Team

1 Team Member

Casdin Capital has 1 team member, including current Founder, Chief Investment Officer, Eli Casdin.

Name

Work History

Title

Status

Eli Casdin

AllianceBernstein, Bear Stearns, and Cooper Hill Partners

Founder, Chief Investment Officer

Current

Name

Eli Casdin

Work History

AllianceBernstein, Bear Stearns, and Cooper Hill Partners

Title

Founder, Chief Investment Officer

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.